Obvious Demand, Overlooked Businesses

In most corners of the market, once something becomes obvious, it also becomes crowded; that is what market efficiency is supposed to look like. Small companies are different. A business can be understandable, strategically advantaged and trading at an attractive price, while still being largely ignored. The problem is not always one of visibility—often it is one of ownership. Many institutions cannot buy these companies, many analysts do not cover them and many investors do not spend enough time where the weeds are tallest.

That may leave room for a particular kind of edge: identifying durable demand, something that seems obvious or inevitable, before the market fully capitalizes on the small company positioned to serve it.

The work is in identifying the specific business that has a role in addressing a long-term need, possesses a real competitive advantage and has the capacity to suffer when the path proves less linear than headlines may imply. Obvious demand does not guarantee attractive returns. But in small caps, obvious demand can still produce attractive opportunities when the beneficiary is too small, too complex or too underfollowed for the broader market to take note.

Necessary work: Environmental remediation

The need to safely treat hazardous and nuclear waste is not going away. Legacy nuclear sites must be cleaned up, decommissioned facilities must be addressed and environmental obligations do not disappear because investors are focused elsewhere. Yet the small companies that do this work often sit far outside the center of market attention.

Perma-Fix Environmental Services operates in precisely this kind of niche. The company provides hazardous and nuclear waste treatment through specialized facilities supported by regulatory permits, technical know-how and intellectual property developed through years of operating in a difficult industry. This is not a business that can be replicated easily, and it is also not a business where progress is linear. Contract timing can be lumpy, profitability has historically been uneven and the details require more work than many investors are willing to do. That is part of the opportunity. The company is involved in the Hanford cleanup in Washington state, which represents one of the largest and longest-duration environmental remediation projects in the country. We believe the need is clear—the small-company beneficiary is simply less obvious.

Insatiable power demand: The need for nuclear

We think another inevitable and rather obvious example would be our seemingly insatiable power demand. Artificial intelligence, data centers, reshoring, electrification and energy security all point in the same direction: the world will need more reliable power. The exact mix of generation remains uncertain, but it has become increasingly difficult to discuss long-term baseload power without including nuclear energy. If nuclear power is going to remain relevant, let alone expand, fuel supply must exist to support it.

Centrus Energy sits directly in that bottleneck. In our view, the company is uniquely positioned in the domestic nuclear fuel cycle, including enrichment capabilities that are strategically important for both current reactors and the next generation of nuclear technologies. There are significant regulatory barriers, national security considerations and technical requirements that limit the number of viable players in the space. We do not need to predict the exact path of nuclear deployment to understand the importance of domestic fuel supply. The demand for power is visible, but the enrichment bottleneck is less broadly understood. That distinction can create opportunity.

The future is now in health care

Cell and gene therapy remains an exciting area of scientific progress, but can also be an area filled with asymmetric, binary outcomes. We generally do not want to rely on the success or failure of a single therapy; instead, we prefer businesses that provide critical tools to the ecosystem. BioLife Solutions fits that description.

BioLife provides essential materials used to manufacture, store and transport living human cells. These products help keep fragile biological material viable from the lab to the patient. That may sound mundane compared to the promise of the therapy itself, but it is mission critical—if a cell-based therapy cannot be preserved, transported and delivered safely, the science does not reach the patient. The company’s products are a small portion of the customer’s total cost, but they are highly important to the outcome.

Importantly, BioLife’s advantage is reinforced by regulatory familiarity rather than simple product differentiation. Its biopreservation media are supported by FDA Master Files and embedded across approved therapies and clinical trials, while many alternatives remain customer-developed “home-brew” solutions that can add variability and complexity to the regulatory approval and manufacturing process. Once embedded, switching can be difficult due to validation requirements, regulatory filings and manufacturing processes. Progress in cell and gene therapy may be increasingly visible, but the specialized tools enabling that progress can still be underappreciated.

UFP Technologies offers another example of the same idea. The continued growth of robotic surgery is not particularly difficult to imagine. Procedures are becoming more precise, less invasive and increasingly supported by sophisticated devices. The obvious investment conclusion might be to focus on the large device companies at the center of the category, but we are intrigued looking one layer deeper.

UFP is a materials engineering business that helps medical device companies solve complex problems. It brings specialized materials knowledge, customer relationships and process expertise to applications where performance matters. In robotic surgery, for example, single-use components and specialized drapes are necessary parts of the procedure. UFP is not trying to define the future of robotic surgery on its own, but it is enabling that future through a specialized capability that we believe is both difficult to replicate and valuable to the customers that depend on it. The growth of robotic surgery may be obvious. The small materials company quietly participating in that growth may not be.

Clean environments, reliable power, advanced therapies and better surgical outcomes are all durable needs. But durable needs alone do not make good investments. We still require a business-first mentality. We still need to understand the competitive advantages, balance sheet, management team, valuation and the company’s ability to endure periods when the market is not paying attention.

That is why small company investing remains so compelling. The market can recognize a long-term need while still failing to properly value the niche company positioned to serve it. Some businesses are too small for large institutions, too illiquid for short-term capital, too technical for broad coverage or too variable for investors who need every quarter to fit cleanly into a model. We are willing to spend time in those areas because inefficiency is often greatest where convenience is lowest.

Investing in obvious demand is not about pretending the future is certain. It is about identifying areas where the direction of demand is becoming increasingly difficult to dispute, then doing the work to find the companies with the right role, the right moat and the right management team to benefit over time.

The need may be visible. The business may be understandable. The opportunity may even seem obvious. But particularly in underfollowed areas of the market, obvious does not always mean efficiently priced. That is where we believe patience, deep research and a willingness to look where others do not can still create a durable edge.